10.1128/AEM.02628-12 173
We also work to protect your data and privacy with payment systems that encrypt your details in transit
Other mitochondrial citrate cycle enzymes, such as alpha-ketoglutarate dehydrogenase and isocitrate dehydrogenase can also be activated by Ca 2+ [21, 22]
Stakeholders Pharmaceutical & biotechnology companies Hospitals Specialty clinics Long-term care facilities Patient advocacy organizations Academic researchers and government research organizations Private research institutes Contract manufacturing organizations (CMOs) Contract research organizations (CROs) Venture capitalists Report Objectives To define, describe, and forecast the oral proteins and peptides market based on molecule, drug class, therapeutic area, formulation, end user, and region To provide detailed information regarding the major factors influencing market growth (such as drivers, restraints, opportunities, and challenges) To strategically analyze micromarkets with respect to individual growth trends, prospects, and contributions to the overall oral proteins and peptides market To analyze opportunities in the market for stakeholders and provide details of the competitive landscape for market leaders To forecast the size of the market segments with respect to six main regions: North America, Europe, the Asia Pacific, Latin America, the Middle East, and Africa To profile the key players in the oral proteins and peptides market and comprehensively analyze their product portfolios, market positions, and core competencies To track and analyze competitive developments in the oral proteins and peptides market, such as acquisitions, product launches/approvals, expansions, agreements, partnerships, and collaborations To benchmark players within the oral proteins and peptides market using the Company Evaluation Matrix' framework, which analyzes market players based on various parameters within the broad categories of business strategy and product strategy Key Questions Addressed by the Report The key players are Novo Nordisk A/S (Denmark), AbbVie Inc
MIS-C primarily affects children, but can also be found in people up to 21 years old, resulting in inflammation of body parts
F., Garofolini, A., Saunders, B., Bishop, D
